Company Overview of Aridis Pharmaceuticals Inc.
Aridis Pharmaceuticals Inc., a biopharmaceutical company, develops anti-infective product candidates. The company offers AR-301, an anti-Staphylococcus aureus human monoclonal antibody to treat acute pneumonia; AR-101 and AR-104 that are specific lgM monoclonal antibodies, which target pseudomonas aeruginosa; and Aerucin, a broadly reactive monoclonal antibody against Pseudomonas aeruginosa. It also provides Panaecin, a small molecule anti-infective gallium compound with broad spectrum activities against bacteria, viruses, and fungi; AR201, a human monoclonal antibody, which treats respiratory syncytial virus infections; and AR401, a human monoclonal antibody for the treatment of Nosocomial ...
5941 Optical Court
San Jose, CA 95138
Founded in 2003
Key Executives for Aridis Pharmaceuticals Inc.
Co-Founder, Chief Executive Officer and Director
Co-Founder, Chairman and President
Chief Financial Officer and Director
Compensation as of Fiscal Year 2015.
Aridis Pharmaceuticals Inc. Key Developments
Aridis Pharmaceuticals, Inc. Receives U.S. Food and Drug Administration Fast Track Designation for AR-301 for Acute Pneumonia Caused by Staphylococcus Aureus
Sep 11 15
Aridis Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration granted Fast Track Designation to AR-301, the company's fully human anti-Staphylococcal alpha-toxin IgG1 monoclonal antibody. AR-301 is currently in Phase 2a clinical trial for the treatment of hospital-acquired and ventilator-associated pneumonia caused by Staphylococcus aureus, including multi-drug resistant MRSA strains. Fast Track designation is a process designed to facilitate the development, and expedite the review of drugs to treat serious conditions and fill unmet medical needs. Companies that receive Fast Track designation are allowed to submit New Drug Applications or Biologics License Applications on a rolling basis, expediting the FDA review process, and benefiting from more frequent communication with the FDA to discuss all aspects of clinical development. Additionally, drugs that receive Fast Track designation are eligible for accelerated approval and priority review. AR-301 is a fully human immunoglobulin G1, or IgG1, mAb targeting Gram-positive Staphylococcus aureus, or S. aureus, bacteria, including methicillin-resistant S. aureus, which is currently in a Phase 2a clinical trial in HAP and VAP patients. Â The clinical study is a randomized, double-blind, placebo-controlled study in 52 patients comparing the safety and efficacy of AR-301 as adjunctive therapy with standard-of-care antibiotics versus antibiotics alone. AR-301 is designed to be effective on bacterial infections whether or not they are resistant to conventional antibiotics. Â AR-301 has already demonstrated strong prophylactic and therapeutic efficacy in mouse models of S. aureus pneumonia and has also been granted Orphan Drug designation in the European Union.
Aridis Pharmaceuticals Inc. Appoints Fred Kurland as Chief Financial Officer
Jul 14 15
Aridis Pharmaceuticals Inc. announced the appointment of Fred Kurland, a seasoned pharmaceutical executive, as the company's first Chief Financial Officer. Prior to joining the company, Fred Kurland served as Chief Financial Officer, Vice President of Finance and Secretary of XOMA Corporation since December 2008. He was responsible for directing the company's financial strategies and financing activities.
Aridis Pharmaceuticals Expands Phase 2a Trial into the U.S. for Monoclonal Antibody AR-301 for the Treatment of Acute Pneumonia
Jul 8 15
Aridis Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for AR-301, also referred to as Salvecin™, the company's fully human anti-Staphylococcal a-toxin IgG1 monoclonal antibody being developed for the treatment of hospital-acquired and ventilator-associated pneumonia (HAP and VAP) caused by Staphylococcus aureus, including multi-drug resistant 'MRSA' strains. Acceptance of the IND application enables Aridis to expand and accelerate its current Phase 2a study of AR-301 as an adjunctive therapy with standard-of-care antibiotics into the United States. The study is currently underway in three European countries, with further expansion into the United Kingdom also planned. Top-line results from the accelerated Phase 2a study are expected in the first half of 2016. The European Phase 2a clinical trial is a randomized, double-blind, placebo-controlled, single ascending dose study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of a single intravenous administration of AR-301 in patients with severe pneumonia caused by S. aureus. Depending on the outcome of Phase 2a clinical trial, Aridis expects the subsequent phase of clinical testing of AR-301 to be either a Phase 2b trial, followed by a Phase 3 trial in pneumonia patients. AR-301 was discovered by screening B-cell lymphocytes of a patient with confirmed S. aureus infection and developed using Aridis' proprietary MAbIgX® technology. It binds and neutralizes S. aureus alpha toxin, preventing alpha toxin-mediated destruction of human cells. There is no anti-infective on the market that specifically neutralizes the pathogenic affects brought about by S. aureus toxins and Aridis believes that this mechanism of action complements the bacterial killing properties of many conventional antibiotics, as the bacterial toxins left behind following antibiotic-mediated killing can still be neutralized by AR-301.
Similar Private Companies By Industry
Recent Private Companies Transactions
November 4, 2015